Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety, tolerability, pharmacokinetics and RP2D
(Recommended Phase II Dose) of orally administered HZ-A-018 in patients with B cell lymphoma
who have at least failed or relapsed after first-line treatment.